ARTICLE SUMMARY:
Since its spin-off from Baxter a decade and a half ago, Edwards Lifesciences has transformed itself from a niche player in relatively unexciting segments of cardiovascular devices to a powerhouse in CV and a leader in transcatheter aortic valves. An interview with Mike Mussallem.
Fifteen years ago, the notion that Edwards Lifesciences Corp. would one day stand among the leaders in cardiovascular devices was unthinkable.
